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Distinct HLA class II alleles determine antibody response to vaccina-
tion with hepatitis B surface antigen. Major histocompatibility complex
(MHC) determinants control antibody production in response to protein
antigens. Vaccination with hepatitis B surface antigen (HBsAg) frequently
fails in hemodialyzed patients, but the genetic factors that modulate
humoral responsiveness are poorly characterized. We studied the distri-
bution of HLA class II alleles in 415 hemodialyzed Caucasian patients who
received a full course of HBsAg vaccination, using class II oligotyping
after genomic amplification of the DRB1 and DQB1 loci. Phenotype
frequencies were compared in 114 non responders (anti-HBs antibodies #
10 SI units/liter), 301 responders (anti-HBs antibodies .10 units/liter) and
471 healthy controls. DRB1*01 (DR1) and DRB1*15 (DR15) frequencies
were lower in nonresponders than in responders and controls (DR1,
12.3% vs. 22.9% and 24.8%, respectively; DR15, 14% vs. 22.9% and
25.1%), while DRB1*03 (DR3) and DRB1*14 (DR14) frequencies were
higher (DR3, 32.5% vs. 16.6% and 25.3%, respectively; DR14, 9.6% vs.
3% and 6.6%). Overall, 44.5% of DR3 or DR14 patients were nonre-
sponders, compared to 18.1% of DR1 or DR15 patients (P 5 0.0001). In
conclusion the humoral response to HBsAg vaccine is influenced by class
II allelic variants, which differ in their capacity to bind and present
peptides to T lymphocytes.
The effector mechanisms that underlie the protection conferred
by vaccination are not fully understood. Several factors, such as
the type and dose of antigen, and the route of vaccine adminis-
tration, may contribute to vaccine unresponsiveness. In addition,
genetic factors corresponding to the so-called immune response
(Ir) genes of the major histocompatibility complex (MHC) region
have been shown to control the ability to mount an effective
response to protein antigens [1]. For instance, congenic mice
strains respond differently to hepatitis B virus surface antigen
(HBsAg) according to their H-2 phenotype [2, 3]. Population-
based studies suggest that MHC genes may not only regulate
resistance to infectious agents, as in the case of malaria [4] and
human immunodeficiency virus (HIV) infection [5, 6], but also
determine the outcome of infectious diseases such as leprosy [7,
8], leishmaniasis [9, 10], onchocerciasis [11], papillomavirus-
induced cervical carcinoma [12], and HIV infection [13, 14]. The
course after hepatitis B virus (HBV) infection (clearance of the
virus, persistent infection or chronic active hepatitis) seems to be
determined by the host’s immune response genes [15–20].
Multiple histocompatibility complex genes may also control the
efficiency of the humoral response to vaccination. For example,
the DPB1*0501 allele correlates with enhanced antibody re-
sponses to vaccination with a malaria sporozoite antigen in Thai
subjects [21]. A significant proportion of HBsAg vaccinees, par-
ticularly hemodialyzed patients, fail to respond or develop very
low antibody titers [22, 23]. In Caucasians, poor responsiveness to
HBsAg vaccine is associated with the DR3 and/or DR7 alleles
[24–28], especially when they are present on the extended haplo-
types HLA B8-DR3-SC01 and HLA B44-DR7-FC31. The Bw54-
DR4-DQW4 haplotype has been linked to poor vaccine responses
in Japanese subjects [29–31]. However, most studies involved a
limited number of alleles and small groups of nonresponders,
meaning that the results were rarely statistically significant. Fur-
thermore, different HLA alleles have been incriminated in studies
based on serologic HLA typing, a method that gives only partial
information as it assigns a large number of alleles to the same
serologic specificity.
We investigated HLA class II-linked mechanisms controlling
responsiveness to HBsAg in a large group of hemodialyzed
patients having received well-defined HBs vaccination protocol.
METHODS
Subjects
A total of 415 hemodialyzed Caucasian patients (218 males and
197 females) were recruited in seven French hemodialysis units.
The vaccine consisted of either HBs protein purified from pooled
plasma of HBsAg-positive subjects (Hevac B, Pasteur Me´rieux;
224 patients) or recombinant HBsAg (GenHevac, Pasteur
Me´rieux; 191 patients), the immunogenic potency of both vaccines
being very similar [32]. All the subjects received a reinforced
vaccination protocol, with three doses of HBs vaccine adminis-
tered at monthly intervals, a fourth injection two months later,
and additional injections at two-month intervals, if needed, until
the anti-HBs titer exceeded 50 SI units/liter. Some patients
received up to 10 doses. The anti-HBs humoral response was
measured by means of conventional radioimmunoassay following
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the third and fourth injections and after each subsequent injec-
tion, and was expressed in standard international units (SIU) of
anti-HBs antibodies per liter. Nonresponse was defined by an
antibody titer of 10 SIU/liter of less following the fourth vaccine
injection, whatever the response to additional injections.
The control population consisted of 471 randomly selected
healthy Caucasian blood donors representative of the French
Caucasian population.
Human lymphocyte antigen typing
Human lymphocyte antigen (HLA) class II DNA typing was
performed by means of hybridization with sequence-specific oli-
gonucleotide probes following amplification of the HLA-DRB1
and DQB1 genes in the polymerase chain reaction (PCR) as
previously described [33].
Statistical analysis
Combined chi-square tests were used to determine heteroge-
neity values for all alleles detected at each locus. Allele-specific
associations with antibody responses were then identified by using
a 2 3 2 chi-square (X2) test, or Fisher’s exact test if any value was
less than five. Odds ratios (OR), calculated with Woolf’s formula
and given with 95% confidence intervals, reflect the likelihood of
carrying a particular HLA allele in the non responder group
compared with the responder group. The level of significance was
set at P , 0.05.
Median anti-HBs antibody responses were compared between
patients with a given allele by using the nonparametric Mann-
Whitney test.
RESULTS
Characteristics of patients
The mean age of dialysis patients at start of vaccination was
59.6 6 1.6 years (mean 6 SEM). All 415 patients were hemodia-
lyzed three times per week, with a mean duration of each dialysis
session of 4.1 6 0.1 hours, that is, a median weekly dialysis time
of 12 hours. High-flux membranes were used in 45% of patients,
and bicarbonate buffer was used in 78% of patients. The mean
Kt/V of urea was 1.21 6 0.02 and the mean urea reduction ratio
was 0.67 6 0.03. All patients were recommended a protein
intake $ 1 g/kg body wt/day and a caloric intake $ 30 kCal/kg
body wt/day. All were in good nutritional condition, as assessed by
a mean body mass index (body weight over square height, kg/m2)
of 23.1 6 0.8 in males and 21.8 6 0.9 in females. Mean
hemoglobin level was 11.2 6 0.2 g/dl, with a mean corpuscular
volume of 95.5 6 1.1 m3, 63% of patients being treated with
recombinant erythropietin. Serum ferritin was 338 6 35 mg/liter
and transferrin saturation ratio 24 6 1.8%. Serum albumin was
39 6 1 g/liter and serum transferrin 2.2 6 0.1 g/liter. All patients
received supplementation with folic acid (5 mg/day) and intrave-
nous iron as needed to maintain serum ferritin . 200 mg/liter.
They received as a mean 0.25 mg calcitriol per day. None had
concurrent acute illness at the time of vaccination.
Response to HBsAg vaccine
The humoral response to HBs vaccine was bimodal: 72.5% of
hemodialyzed vaccinees (N 5 301) developed anti-HBs titers
exceeding 10 SIU/liter after the fourth injection and were consid-
ered as responders; the remaining 27.5% (N 5 114) of patients
had titers of 10 SIU/liter or less after the fourth injection (and in
some cases after up to 10 injections) and were considered as
nonresponders. No correlation was found between responder
status and gender, age at the time of vaccination, the type of initial
nephropathy leading to hemodialysis, or the type of vaccine
(plasma-derived or recombinant).
HLA-DRB1 and DQB1 phenotypes
Phenotype frequencies did not differ between the entire group
of hemodialyzed patients and the control group (combined X2 5
16.5 for DRB1, P 5 0.17; and X2 5 19.4 for DQB1, P 5 0.11).
Table 1 compares the frequencies of DRB1 and DQB1 alleles
in the responders and nonresponders with those in the healthy
controls. Analysis of the combined phenotype frequencies for
each class II locus in the responder and nonresponder groups
showed that alleles of the DRB1 locus correlated with the vaccine
response (x2 5 30.84, P 5 0.0021), whereas those of the DQB1
locus did not (x2 5 12.5, P 5 0.48).
Frequencies of DRB1*01 (DR1) and DR2 [both DRB1*15
(DR15) and DRB1*16] were lower in nonresponders than in
responders (OR 5 0.47, CI 0.25 to 0.87, P 5 0.02; OR 5 0.55, CI
0.30 to 0.99, P 5 0.05, respectively). These differences corre-
sponded to lower frequencies of DR1 and DR15 phenotypes in
nonresponders than in controls (DR1, 12.3% in non responders
vs. 24.8% in controls, P 5 0.003; DR15, 11.4% vs. 20.8%, P 5
0.023).
By contrast, DRB1*03 (DR3) and DRB1*14 (DR14) pheno-
type frequencies were higher in nonresponders than in responders
(OR 5 2.42, CI 1.46 to 3.96, P 5 0.0007; OR 5 3.46, CI 1.39 to
8.6, P 5 0.008, respectively). These differences were related to
lower frequencies of DR3 and DR14 in responders than in
controls (DR3, 16.6% vs. 25.3%, P 5 0.005; DR14, 3% vs. 6.6%,
P 5 0.03). The frequencies of DR3, DR14, DR15 and DR1
homozygous patients were similar in the nonresponder and re-
sponder groups, and were in keeping with calculated gene fre-
quencies (data not shown).
Overall, a response to HBs vaccine was positively associated
with the DR1 and DR15 phenotypes, and negatively associated
with the DR3 and DR14 phenotypes (Table 2). Among DR3
and/or DR14 patients, 44.5% were nonresponders, compared to
only 18.1% of DR1 and/or DR15 patients (P 5 0.0001).
Accordingly, the median anti-HBs antibody titer was signifi-
cantly lower in DR3 patients (20 SIU/liter) and in DR14 patients
(10 SIU/liter) than in DR1 patients (33 SIU/liter, P 5 0.0012 and
P 5 0.003, respectively) and in DR15 patients (30 SIU/liter, P 5
0.0046 and P 5 0.008, Mann-Whitney test).
DISCUSSION
Overall, the DR3 and DR14 phenotypes were associated with a
poor humoral response to HBsAg vaccination, whereas the DR1
and DR15 phenotypes were associated with a good response. We
studied hemodialyzed patients because of their well-known hypo-
responsiveness to HBsAg vaccine [22, 23], giving us the opportu-
nity to analyze a population with a high proportion of nonre-
sponders. The links we observed were not due to a distortion of
HLA allelic frequencies in hemodialyzed patients, as there was no
difference in the overall phenotype distribution between the
entire hemodialysis group and a healthy control group of similar
geographic origin.
The weak response of uremic dialysis patients to hepatitis B
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vaccine cannot be ascribed to inadequate dialysis or poor nutri-
tional status, as parameters of adequate dialysis (Kt/V urea, and
urea reduction ratio) and nutrition (serum albumin level and body
mass index) were in the optimal range of values [34].
The main function of HLA class II gene products is to bind
antigenic peptides derived from exogenous proteins and to
present them, at the cell surface, to the T cell receptor on CD41
T lymphocytes. Allelic differences in HLA molecules can modu-
late their ability to bind peptides, and thereby change the nature
of T cell recognition. Previous reports have described associations
between HLA class II alleles and HBsAg vaccine responses
[24–31], but their interpretation has often been controversial. In
Caucasians, the HLA A1-B8-DR3 haplotype has been shown to
induce a recessive inability to develop anti-HBs antibodies, par-
ticularly in homozygotes. Various immunological mechanisms,
most of which have now been rejected, have been proposed to
explain this lack of response:
(a) the absence of dominant Ir genes located in the MHC [24,
26, 35];
(b) defective antigen-presenting cell/T cell interactions [36, 37],
possibly due to a lack of binding of HBsAg peptides to HLA
molecules or to an absence of a co-stimulatory signal, leading to
inefficient presentation to CD41 helper T cells;
(c) elimination of HBsAg-specific helper T cells during thymic
or post-thymic repertoire maturation, or inactivation by periph-
eral anergy [38];
(d) selective killing of HBsAg-specific B cells by MHC-re-
stricted cytotoxic T lymphocytes [39];
(e) the presence of dominant immune suppression (Is) genes, a
possibility raised by the induction of Ag-specific suppressor T cells
in Japanese subjects with the extended Bw54-DR4-DRw53-DQw4
haplotype [29, 30];
(f) one may also propose another mechanism, given recent
insights. Protein antigens tend to elicit predominantly one of two
T-helper cell (Th) subsets that have different patterns of cytokine
production [reviewed in 40]. Following stimulation, antigen-spe-
cific T cells progress from naı¨ve cells to Th0 cells that further
differentiate into Th1 or Th2 cells. Th1 cells mainly produce
interleukin (IL)-2, tumor necrosis factor (TNF) and interferon-g
(IFNg), thereby favoring cellular immune responses such as
macrophage activation and delayed-type hypersensitivity (DTH).
Th2 cells mainly produce IL-4, IL-5, IL-6 and IL-13, cytokines
that not only stimulate humoral responses but can also suppress
Th1 cellular responses. Th1 and Th2-type responses are thus
antagonistic.
Microbial pathogens frequently elicit polarized responses of
either the Th1 or Th2 type, probably because they alter the
cytokine milieu during initial antigen priming. Other factors may
also influence which T cell subset dominates after infection [41].
One may imagine that some alleles, such as DR3 and DR14,
preferentially induce a Th1 (cellular) response, which would
inhibit the Th2 (humoral) response and limit the production of
anti-HBsAg antibodies. Conversely, the response would be
skewed towards Th2 responsiveness in subjects with DR1 and
DR2 alleles. This hypothesis fits with the low DR3 and DR14
frequencies in responders, and the low DR1 and DR2 frequencies
in nonresponders, and can reconcile discrepancies among previ-
ous studies, which have been attributed to differences in ethnic
group or in the route of HBsAg vaccination. Similar MHC-linked
Table 1. DRB1 and DQB1 phenotype frequencies in control subjects, and in responders and nonresponders to HBsAg vaccine
DRB1*
Controls
(N 5 471)
Nonresponders
(N 5 114)
Responders
(N 5 301) ORa (95%
confidence interval) PN % N % N % (¶)
01 117 24.8 14 12.3b 69 22.9 0.47 (0.25–0.87) 0.02
02 (15116) 118 25.1 16 14.0c 69 22.9 0.55 (0.30–0.99) 0.05
15 98 20.8 13 11.4d 52 17.3
16 20 4.2 3 2.6 17 5.6
03 119 25.3 37 32.5 50 16.6e 2.42 (1.46–3.96) 0.0007
04 93 19.7 26 22.8 78 25.9
11 107 22.7 32 28.1 85 28.2
12 16 3.4 3 2.6 9 3.0
13 110 23.4 29 25.4 73 24.3
14 31 6.6 11 9.6 9 3.0f 3.46 (1.39–8.6) 0.008
07 121 25.7 26 22.8 70 23.3
08 29 6.2 4 3.5 20 6.6
09 9 1.9 1 0.9 8 2.7
10 13 2.8 7 6.1 9 3.0
a Only significant risks are indicated.
b P 5 0.003, c P 5 0.012, d P 5 0.23, x2 test for heterogeneity between nonresponders and controls.
e P 5 0.005, f P 5 0.03, x2 test for heterogeneity between responders and controls.
Table 2. AntiHBsAg antibody response according to DR phenotype
DRB1* phenotype N
Anti-HBs antibody titer
P
.10 IU/liter
N (%)
,10 IU/liter
N (%)
DRB1*03 87 50 (57.5) 37 (42.5)
non-DRB1*03 328 251 (76.5) 77 (23.5) 5 0.0007
DRB1*14 21 10 (47.6) 11 (52.4)
non-DRB1*14 394 291 (73.8) 103 (26.1) 5 0.02
DRB1*01 83 69 (83.1) 14 (16.9)
non-DRB1*01 332 232 (69.9) 100 (30.1) 5 0.018
DRB1*15 66 53 (80.3) 13 (19.7)
non-DRB1*15 349 248 (71) 101 (28.9) 5 0.13, NS
DRB1*3 or DRB1*14 108 60 (55.5) 48 (44.4)
DRB1*1 or DRB1*15 149 122 (81.9) 27 (18.1) , 0.0001
NS is not significant.
Caillat-Zucman et al: HLA and hepatitis B vaccine1628
mechanisms might regulate susceptibility to various infections.
Indeed, the type of Th cell response to certain pathogens can
differ according to the MHC haplotype of mouse strains [42]. In
humans, the course after HBV infection is determined by the
HLA phenotype. Association between the A1-B8 haplotype and
clearance of HBV in hemodialyzed patients has long been de-
scribed [15, 16], and suggests that this haplotype, which usually
bears the DR3 allele due to linkage disequilibrium, might be
associated with high Th1 response against HBsAg. The frequency
of DR3 is increased in patients with HBV chronic active hepatitis
in comparison with healthy carriers [17, 18]. In Gambia, the
DRB1*1302 allele is associated with protection against persistent
HBV infection [20], whereas DR7, but not DR2 subjects fre-
quently develop chronic HBV infection in Katar [19]. The clinical
disease induced by Mycobacterium leprae is also influenced by
HLA class II alleles: the DR3 and DR2 haplotypes confer a high
risk of polar tuberculoid leprosy, which is associated with strong
DTH reactions and low antibody levels (Th1 response), whereas
other alleles are associated with the multibacillary lepromatous
form characterized by excessive production of nonprotective
antibodies (Th2 response) [7, 8, 43, 44]. Susceptibility to muco-
cutaneous leishmaniasis, a strong DTH reaction caused by Leish-
mania braziliensis infection, is associated with a higher frequency
of the DR3-TNF-b2 haplotype and a lower frequency of the DR2
haplotype [45]. The A1 B8 DR3 haplotype is associated with rapid
disease progression in HIV-seropositive individuals, whereas re-
sistance to infection among frequently exposed prostitutes is
associated with DR13 [13, 14]. DR2 and DR5 are associated with
an IgE allergic response (Th2) to Aspergillus fumigatus in bron-
chomulmonary aspergillosis [46]. Finally, known associations be-
tween HLA and susceptibility to autoimmune diseases are also in
keeping with this hypothesis. In an animal model of collagen
IV-induced arthritis, a single peptide can induce a Th1 or a Th2
response depending on the MHC genotype [47]. The DR3
haplotype, which predisposes humans to insulin-dependent dia-
betes mellitus, is associated with a cellular response (Th1) leading
to immune destruction of pancreatic b cells, whereas the strongly
protective DR15 haplotype might antagonize this Th1 response.
Crystallography of MHC class II molecules has revealed that
peptides are accomodated in a polymorphic binding groove [48].
Allelic differences in amino acid residues located within the
groove directly affect binding affinity for particular peptides. It
appears that high-affinity ligands shift the lymphokine-secretion
pattern towards a Th1-like response [39, 47]. The products of
HLA class II alleles associated with strong and weak responses to
HBsAg differ structurally, with nonconservative amino acid sub-
stitutions occurring mainly in the first hypervariable region,
between residues 9 to 13. Based on the three-dimensional model
of the class II antigen-binding cleft [48], these positions are
thought to influence interactions with peptide residues. Knowl-
edge of the relative binding affinities of HBsAg peptides for class
II molecules associated with strong and weak responses to the
vaccine might lead to strategies for controlling the type of helper
T cells activated in response to defined antigens.
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APPENDIX
Abbreviations used in this article are: DR1, DRB*01 phenotype; DR3,
DRB*03 phenotype; DR14, DRB*14 phenotype; DR15, DRB1*15 phe-
notype; DTH, delayed-type hypersensitivity; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; HIV, human immunodeficiency virus;
HLA, human lymphocyte antigen; IFNg, interferon-g; IL, interleukin; Is,
immune suppression; MHC, multiple histocompatibility complex; OR,
odds ratio; PCR, polymerase chain reaction; SIU, standard international
units; Th, T helper cell; TNF, tumor necrosis factor.
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